This activity is part of the ConnectED Learning: Diabetes curriculum. It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic live educational program will feature renowned faculty experts who will lead an interactive discussion on important evidence supporting emerging clinical strategies, shared decision making, and ways in which to individualize care to best manage the complex challenges of diabetes and the progression of disease. It will include therapeutic approaches that can reduce the risks such as hypoglycemia, weight gain, and cardiovascular events.
This activity is part of the ConnectED Learning: Diabetes curriculum. Join expert faculty as they address your remaining questions and provide a distillation of clinical pearls from the ConnectED Learning Curriculum on the management of diabetes
This activity is part of the ConnectED Learning: Diabetes curriculum. In this Expert Perspective, Dr. Richard Pratley outlines the main facets of utilizing oral combination therapy to intensify treatment in order to achieve HbA1c goals while minimizing side effects and cardiovascular risk.
This activity is part of the ConnectED Learning: Diabetes curriculum. This case will highlight best practices of intensifying therapy with oral combination regimens in individuals with T2DM.
Follow the complex case of a 55-year-old patient who presents with long-standing, uncontrolled type 2 diabetes requiring individualized care. Filled with common scenarios relevant to primary care, this case distinguishes nuances in management based on patient- and disease-specific factors while enhancing your knowledge on the myriad diabetes therapies available today.
This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin analogs are essential antihyperglycemic therapies for many patients with type 2 diabetes mellitus (T2DM) (eg, those in need of large glucose-lowering effects or, based on recent updates to the official indications for 2 of the GLP-1 RAs). This Engaging the Patient activity will discuss newer insulin therapies as well as GLP-1 injectable therapies, including rationales and clinical trial evidence for combining these two agents. The activity includes a demonstration of clinician and patient interactions-ways to educate patients on the use of injectable medications, as well as approaches to reducing hypoglycemia and improving patient adherence.
This case outlines nuances of intensifying therapy with oral antidiabetic agents based on patient and disease characteristics
Through real-time interaction with faculty, learners will evaluate the differences between conventional and newer basal insulins and review the clinical impact of hypoglycemia, as well as the strategies for detecting, preventing, and managing hypoglycemia.
In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).
It is well proven that effective glycemic control among patients with type 2 diabetes can reduce the risk of diabetes-related microvascular and macrovascular complications. This dynamic and interactive live educational program will feature renowned faculty experts who will lead an interactive discussion of important evidence supporting the use of individualized oral combination therapy to attain glycemic control while minimizing weight gain, as well as hypoglycemic and CV risk.